Key Takeaways on Evolving Treatment Landscape in Multiple Myeloma
The expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
MM Treatment: Clinical Advice on the Care of Patients Receiving Talquetamab
Tiffany Richards, PhD, ANP-BC, and the rest of the panel offer clinical advice on the care of patients with multiple myeloma who are receiving talquetamab.
The Role of a GPRC5D-Targeting Bispecific in Relapsed/Refractory MM
Beth Faiman, PhD, MSN, describes the role of a GRPC5D-targeting bispecific antibody, talquetamab, in the treatment of patients with relapsed/refractory multiple myeloma.
Managing Talquetamab-Associated Toxicities in Patients with MM
Comprehensive insights on the management of toxicities seen in patients with multiple myeloma who are receiving talquetamab.
Educating Patients on Adverse Effects Related to Talquetamab in MM
Expert perspectives on educating patients with multiple myeloma on adverse effects related to treatment with talquetamab.
Treatment Sequencing and the Role of Talquetamab in MM
Clinical insights on treatment sequencing and the role of talquetamab, highlighting its safety profile in patients with multiple myeloma.
Patient Scenario Cont’d: Treatment in Late-Line Relapsed MM
Turning the focus back to the clinical scenario, Donna Catamero, ANP-BC, OCN, CCRC, discusses the patient’s repeat diagnostic workup and the panel provides their insights on treatment decisions.
Resources for Educating Patients with Myeloma
Focusing on patient education, the panel outlines resources available to help patients with multiple myeloma navigate their treatment journey.
Patient Scenario: A 63-Year-Old Man with Multiple Myeloma
A panel of experts on multiple myeloma review a patient profile, offer their initial impressions, and highlight the role of an advanced practice provider.
